Here’s Why Abbott Laboratories (ABT) Traded Down in Q3

Core Insights - The S&P 500 Index experienced a year-to-date return of 13.7% in the third quarter of 2025, with growth and momentum being significant contributors to this performance [1] - The market's current strength is heavily reliant on AI deployment, indicating that any weaknesses in this area could pose risks to future market performance [1] Company Analysis: Abbott Laboratories (NYSE:ABT) - Abbott Laboratories reported a one-month return of -1.89% and a 52-week loss of 9.73%, with its stock closing at $127.00 on November 11, 2025, and a market capitalization of $220.837 billion [2] - The company underperformed in the third quarter due to disappointing second-quarter financial results and a downward revision of its financial guidance, particularly facing challenges in its diagnostics segment in China due to economic conditions and pricing pressures [3] - Abbott Laboratories is not among the 30 most popular stocks among hedge funds, with 69 hedge fund portfolios holding its stock at the end of the second quarter, a slight decrease from 70 in the previous quarter [4]